A Single-arm, Open-label, Multi-center Phase 2 Study of Enfortumab Vedotin (ASG-22CE) in Chinese Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy (EV-203)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Adenocarcinoma; Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms EV-203
- Sponsors Astellas Pharma China
- 06 Nov 2023 Planned End Date changed from 31 Jan 2024 to 30 Sep 2024.
- 06 Jun 2023 Results assessing the efficacy, safety/tolerability, and pharmacokinetics of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 26 Apr 2023 According to Seagen media release, an abstract (Abstract NO. e16574) including the data of patients with previously treated advanced urothelial carcinoma will be present at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago.